

## LUST Study

The LUST study is a randomized clinical trial aiming at testing a treatment policy guided by extra-vascular lung water measurements by ultrasound to prevent death, decompensated heart failure and myocardial infarction as well as progression of LVH and LV dysfunction and hospitalization in high risk dialysis patients with myocardial ischemia (a history of myocardial infarction with or without ST elevation or unstable angina, acute coronary syndrome documented by ECG recordings and cardiac troponins or stable angina pectoris with documented coronary artery disease by prior coronary angiography or ECG) or overt heart failure (NYHA class III-IV).

Tab. 1: number of patients enrolled and registered in the LUST database per centre.

The present composition of the LUST workgroup involves 19 European Centres (see Table 1 below). In previous reports you might have noticed the Versilia Hospital – Viareggio, Italy which is no longer present because it left the study due to logistical problems. However, the interest in lung congestion is still high and a new centre in Sarajevo, Bosnia, recently joined the study and it started the enrolment of patients. As of January 2018 and according to data already entered in the web platform, 399 patients were enrolled in the study.

Centre	N° of enrolled patients
Barcelona	21
Fléury	8
Hannover	6
Homburg	30
Iasi	20
Ioannina	22
Kallithea	20
Jerusalem	22
Katowice	25
Maribor	33
Nancy	12
Paris	17
Parma	12
Reggio Calabria	37
Saint Augustin	10
Strasbourg	10
Sarajevo	20
Thessaloniki	41
Wroclaw	33
<b>TOTAL</b>	<b>399</b>

The first follow-up visit was performed on 233 patients while 200 had the second follow-up visit. The study was completed in

Reggio Calabria, Maribor, Ioannina, Parma and Wroclaw, whereas Homburg and Iasi are

going to perform the final visits by November 2017. However, our aim is to continue the enrolment in Reggio Calabria, Maribor and Homburg in order to compensate the withdrawal of centres which step out of the study.

The web platform is still constantly monitored in order to check data completeness.

Skype meetings are periodically scheduled with the national coordinators, in order to stimulate data entering and to solve any issues related to the study logistics.

Thanks to the constant surveillance and the WEB meetings, the number of patients and the completeness of the database is continuously improving.

We have to underline that enrolment will be officially closed at the end of December, 2017. Results of planned interim analyses will be circulated in the coming months.

Prof. Carmine Zoccali  
LUST Study Coordinator

### **EURECA-m Registry**

In 2016, a new centre (Thessaloniki, Greece, headed by Prof. Sarafidis) joined the EURECA-m Registry and there are currently 6 centres involved.

The number of patients enrolled so far by centres are reported below:

1. Thessaloniki, Greece (208 pts.)
2. Reggio Calabria, Italy (113 pts.)
3. Parma, Italy (72 pts.)
4. Ioannina, Greece (67 pts.)
5. Homburg/Saar, Germany (40 pts.)
6. Iasi, Romania (7 pts.)

The total number of patients is now 507, and, even though completeness of data is not fully satisfactory, the Registry has enormous potential, being one of the largest Registries collecting high quality, fully validated 48h-ABPM, Pulse Wave Velocity (PWV) and Echocardiography data in dialysis patients. To date, 48h-ABPM measurements are available in 315 patients.

As we have already stated in previous newsletters, a new study as a spin-off of the Registry was proposed with two major aims: 1) to confirm in a large unselected HD population in Europe, the findings previously described in a series of Afro-American dialysis



patients by Agarwal (CJASN 2006; 1: 389–398) and 2) to test ABPM feasibility and tolerability in HD patients and in a well-matched group of essential hypertensives (EH).

We aim at enrolling about 1000 patients and if we reach this target it will be the largest collection of 48-ABPM in haemodialysis patients ever recorded.

The first patient for this new protocol was enrolled in January 2016 in Maribor, Slovenia and then 11 European centres joined the study (Reggio Calabria, Roma - Colleferro, Acireale, Roma - Ostia, Viareggio, Bari, San Giovanni Rotondo, Como, Foggia and Palermo, Italy and Thessaloniki, Greece). So far, the number of patients enrolled is 396 (354 HD and 42 EH). For each patient, ABPM recording is available and, should it not be completed all the reasons relating to premature stops are accurately recorded. Data collection is still ongoing and partial data collected so far have already been sent to Reggio Calabria, which is the coordinating centre, and registered in the database.

This new study will hopefully give us the opportunity to broaden the dataset already present and to increase the number of patients for the ongoing analysis proposed by Prof. Sarafidis, i.e. to investigate the pattern of hypertension in dialysis patients.

Prof. Francesca Mallamaci  
EURECA-m Registry Clinical Coordinator